z-logo
Premium
Phenylbutazone, a New Long‐Acting Agent that can Improve the Peptide Pharmacokinetic Based on Serum Albumin as a Drug Carrier
Author(s) -
Zhou Jie,
Li Xue,
Zhu Xiaoyun,
Sun Jian,
Qiu Qianqian,
Huang Wenlong,
Qian Hai
Publication year - 2016
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12726
Subject(s) - peptide yy , pharmacokinetics , agonist , phenylbutazone , chemistry , pharmacology , albumin , human serum albumin , peptide , linker , serum albumin , appetite , receptor , endocrinology , conjugate , medicine , biochemistry , neuropeptide , neuropeptide y receptor , computer science , operating system , mathematical analysis , mathematics
As a NPY ‐2 receptor agonist, PYY 24–36‐ Leu 31 is reported to suppress appetite and has a potential in obesity treatment, but its short half‐life limits the clinical application. The use of chemical modification to improve interactions with human serum albumin ( HSA ) is an effective strategy for prolonging the half‐lives of peptide analogues. So based on the characteristics that phenylbutazone has a good combination with HSA , we selected a proper linker to link with PYY 24–36 ‐Leu 31 to create long‐acting and highly biologically active PYY 24–36 ‐Leu 31 conjugates, and successfully find a novel, long‐acting PYY 24–36 ‐Leu 31 conjugate 8 that, when dosed every other day in diet induce obese ( DIO ) mice for 2 weeks, results in a significant reduction in food intake and body weight and improvement in blood parameter and hepatic steatosis.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here